Loading…
GSK plc is projected to rise to $68.67 by 2027, a +33% move from its current price of $51.58. GSK is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $51.00 | $51.61 | $52.23 | +0.05% |
| May 30 | $50.77 | $51.63 | $52.51 | +0.10% |
| May 31 | $50.61 | $51.66 | $52.74 | +0.16% |
| Jun 1 | $50.47 | $51.69 | $52.94 | +0.21% |
| Jun 2 | $50.35 | $51.72 | $53.11 | +0.26% |
| Jun 3 | $50.25 | $51.74 | $53.28 | +0.32% |
| Jun 4 | $50.16 | $51.77 | $53.43 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $50.16 | $51.77 | $53.43 | +0.37% |
| Week 2 | $49.69 | $51.96 | $54.33 | +0.74% |
| Week 3 | $49.38 | $52.15 | $55.08 | +1.11% |
| Week 4 | $49.14 | $52.34 | $55.75 | +1.48% |
| Week 5 | $48.96 | $52.54 | $56.38 | +1.85% |
| Week 6 | $48.81 | $52.73 | $56.97 | +2.23% |
| Week 7 | $48.68 | $52.92 | $57.53 | +2.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GSK plc is a healthcare company that conducts research, development and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments and offers a range of therapies including oncology, respiratory/immunology, inflammation, and HIV treatments, along with vaccines for shingles, meningitis, RSV, seasonal influenza and more. GSK plc was founded in 1715 and is headquartered in London, United Kingdom; it was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
GSK plc is currently priced at $51.38 with a market cap of $103.1B, and it holds a rank of 151 among peers. The stock’s near-term technical backdrop is described as bullish, with a 30-day setup that supports a constructive stance for improved pricing ahead. The market shows a defined support at $49.67 and a resistance at $59.18, with the 30-day trading range spanning $47.26 to $55.86.
A major floor 13.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 13.1% above — a clean break opens room to run.
A major ceiling 20.0% above — clearing it would confirm fresh momentum.
Key GSK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GSK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $51.35 | Buy | $51.35 | Buy |
| MA 10 | $50.97 | Buy | $51.20 | Buy |
| MA 20 | $50.92 | Buy | $51.66 | Sell |
| MA 50 | $53.66 | Sell | $52.95 | Sell |
| MA 100 | $54.02 | Sell | $52.54 | Sell |
| MA 200 | $49.14 | Buy | $49.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.34 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 86.20 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.29 | Buy |
| ROC (12) | 2.32 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | -2.01 | Sell |
| Ultimate (7,14,28) | 70.11 | Sell |
| Momentum (10) | 0.68 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 51.75 | Sell |
| ADX (14) | 21.12 | Sell |
| ATR (14) | 0.54 | Info |
The 30-day technical picture points to bullish sentiment, with RSI(14) at 40 and the price fluctuating within a 30-day range of $47.26 to $55.86. The stock sits above a key near-term level today but remains sensitive to moves within its 30-day window. The moving averages are $53.74 for the SMA50 and $49.00 for the SMA200, with a near-term support at $49.67 and resistance at $59.18.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $47.65 | $51.58 | $66.79 | 0% | Neutral | |
| $56.10 | $68.67 | $87.99 | +33% | Bullish | |
| $63.33 | $78.94 | $103.79 | +53% | Bullish | |
| $69.58 | $88.04 | $118.16 | +71% | Bullish | |
| $74.09 | $94.99 | $129.75 | +84% | Bullish | |
| $77.11 | $100.06 | $138.80 | +94% | Bullish | |
| $84.24 | $110.54 | $155.49 | +114% | Bullish | |
| $91.69 | $121.58 | $173.21 | +136% | Bullish | |
| $106.23 | $142.25 | $205.06 | +176% | Bullish | |
| $118.76 | $160.52 | $233.96 | +211% | Bullish | |
| $164.13 | $231.34 | $353.23 | +349% | Bullish | |
| $275.98 | $417.12 | $682.53 | +709% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $47.65 | $51.58 | $60.62 | +0.00% |
| June 2026 | $46.16 | $53.85 | $64.03 | +4.39% |
| July 2026 | $46.12 | $54.11 | $64.95 | +0.49% |
| August 2026 | $45.38 | $53.48 | $64.67 | -1.16% |
| September 2026 | $45.91 | $54.31 | $66.06 | +1.55% |
| October 2026 | $46.31 | $54.97 | $67.23 | +1.22% |
| November 2026 | $45.40 | $54.05 | $66.41 | -1.68% |
| December 2026 | $45.33 | $54.12 | $66.79 | +0.13% |
Click any year to see its month-by-month GSK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GSK to range from $47.65 to $66.79 through 2026. The $51.58 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The GSK price prediction for 2027 points to an average of $68.67 (low $56.10, high $87.99) — a potential gain of +33% on today's $51.58. Buyers look set to stay in control over this stretch.
In 2028, GSK is projected to trade between $63.33 and $103.79, averaging $78.94 — a potential gain of +53% from today's $51.58. That is up +15% on the projected 2027 average. Momentum favours further upside here.
GSK plc's 2029 outlook centres on $88.04, within a $69.58 to $118.16 range. That is up +12% on the projected 2028 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, GSK could reach as high as $129.75, with a base case around $94.99 and support toward $74.09 — roughly +84% from $51.58. Momentum favours further upside here.
Expect GSK to range from $77.11 to $138.80 through 2031. The $100.06 average target implies a +94% move from current prices. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The GSK price prediction for 2032 points to an average of $110.54 (low $84.24, high $155.49) — a potential gain of +114% on today's $51.58. Momentum favours further upside here.
In 2033, GSK is projected to trade between $91.69 and $173.21, averaging $121.58 — a potential gain of +136% from today's $51.58. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
GSK plc's 2034 outlook centres on $142.25, within a $106.23 to $205.06 range. That is up +17% on the projected 2033 average. That marks a +176% change versus current levels. Momentum favours further upside here.
By 2035, GSK could reach as high as $233.96, with a base case around $160.52 and support toward $118.76 — roughly +211% from $51.58. Buyers look set to stay in control over this stretch.
Expect GSK to range from $164.13 to $353.23 through 2040. The $231.34 average target implies a +349% move from current prices. That is up +44% on the projected 2035 average. Momentum favours further upside here.
The GSK price prediction for 2050 points to an average of $417.12 (low $275.98, high $682.53) — a potential gain of +709% on today's $51.58. Buyers look set to stay in control over this stretch.
Investing $1,000 in GSK today (≈ 19.387359 GSK) could be worth
$8,086.95
+$7,086.95 (+709%) by 2050 · US Dollar
Based on the average projected GSK price of $417.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GSKwould be worth at today's price.
$1,000 invested in GSK on May 27, 2025 (≈ 25.35497 GSK) would be worth
$1,307.81
+$307.81 (+30.8%) today · 1.31× · US Dollar
Based on a GSK entry price of $39.44 vs. today's $51.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $50.78 | $1,015.75 | +1.6% |
| 1 month ago | $54.22 | $951.31 | -4.9% |
| 3 months ago | $58.07 | $888.24 | -11.2% |
| 6 months ago | $47.86 | $1,077.73 | +7.8% |
| 1 year ago | $39.44 | $1,307.81 | +30.8% |
| All time (5.0y) ago | $38.35 | $1,344.98 | +34.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GSK forecast.
Our base-case forecast reaches $100.00 around 2031.
Implied market cap at $100.00: $200.59B
The multi-year forecast shows a gradual upside from 2026 onward, with 2026 min $47.65, avg $51.38 and max $66.76 (ROI 0, sentiment Neutral). From 2027 onward the path strengthens: 2027 avg $68.49 (ROI 33.3%), 2028 avg $78.04 (ROI 51.9%), 2029 avg $87.29 (ROI 69.9%), and 2030 avg $94.17 (ROI 83.3%). The ascent continues through 2031–2035, with 2031 avg $98.50 (ROI 91.7%), 2032 avg $109.29 (ROI 112.7%), 2033 avg $119.86 (ROI 133.3%), 2034 avg $139.55 (ROI 171.6%), and 2035 avg $158.55 (ROI 208.6%).
Longer horizon projections show substantial upside: 2040 avg $225.97 (ROI 339.8%) and 2050 avg $408.86 (ROI 695.8%). These figures reflect estimates across a wide growth path, with higher potential returns indicated in the distant future, but they are not guarantees and depend on multiple uncertain factors.
Tap a question to reveal the answer.
In 2030 the forecasted average price is $94.17, with a minimum of $73.43 and a maximum of $128.65, and an expected ROI of 83.3%.
The projections show bullish sentiment beginning in 2027 with an average price path rising to $68.49 in 2027, $78.04 in 2028, $87.29 in 2029, and $94.17 in 2030, with positive ROI values (e.g., 33.3% in 2027, 51.9% in 2028, 69.9% in 2029, and 83.3% in 2030). These are estimates, not guarantees.
Yes. The forecast shows a max of $201.20 in 2034 and later a max of $345.07 in 2040, indicating prices can exceed $200 in the forecast horizon.
The 2050 forecast is an average of $408.86, with a minimum of $270.49 and a maximum of $669.06, and an estimated ROI of 695.8%.
The current price is $51.38 and the market cap is $103.1B.
GSK plc Community Discussion
0Share your GSK plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.